🇺🇸 FDA
Pipeline program

VENETOCLAX , Epcoritamab, Epcoritamab, VINCRISTINE , Jaypirca 100 mg film-coated tablets, DOXORUBICIN , Jaypirca 50 mg film-coated tablets, CYCLOPHOSPHAMIDE , PREDNISOLONE , LENALIDOMIDE , RITUXIMAB

GCT3013-03

Phase 2 small_molecule active

Quick answer

VENETOCLAX , Epcoritamab, Epcoritamab, VINCRISTINE , Jaypirca 100 mg film-coated tablets, DOXORUBICIN , Jaypirca 50 mg film-coated tablets, CYCLOPHOSPHAMIDE , PREDNISOLONE , LENALIDOMIDE , RITUXIMAB for Chronic Lymphocytic Leukemia is a Phase 2 program (small_molecule) at Genmab A/S with 1 ClinicalTrials.gov record(s).

Program details

Company
Genmab A/S
Indication
Chronic Lymphocytic Leukemia
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials